Literature DB >> 23378579

The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Kaushal Asrani1, Ruth A Keri, Rebeca Galisteo, Sharron A N Brown, Sarah J Morgan, Arundhati Ghosh, Nhan L Tran, Jeffrey A Winkles.   

Abstract

HER2 overexpression occurs in 15% to 20% of all breast cancers and is associated with increased metastatic potential and poor patient survival. Abnormal HER2 activation, either through HER2 overexpression or heregulin (HRG):HER3 binding, elicits the formation of potent HER2-HER3 heterodimers and drives breast cancer cell growth and metastasis. In a previous study, we found that fibroblast growth factor-inducible 14 (Fn14), a member of the TNF receptor superfamily, was frequently overexpressed in human HER2+ breast tumors. We report here that HER2 and Fn14 are also coexpressed in mammary tumors that develop in two different transgenic mouse models of breast cancer. In consideration of these findings, we investigated whether HER2 activation in breast cancer cells could directly induce Fn14 gene expression. We found that transient or stable transfection of MCF7 cells with a HER2 expression plasmid increased Fn14 protein levels. Also, HRG1-β1 treatment of MCF7 cells transiently induced Fn14 mRNA and protein expression. Both the HER2- and HRG1-β1-induced increase in Fn14 expression in MCF7 cells as well as basal Fn14 expression in HER2 gene-amplified AU565 cells could be reduced by HER2 kinase inhibition with lapatinib or combined HER2 and HER3 depletion using siRNA. We also report that Fn14-depleted, HER2-overexpressing MCF7 cells have reduced basal cell migration capacity and reduced HRG1-β1-stimulated cell migration, invasion, and matrix metalloproteinase (MMP)-9 expression. Together, these results indicate that Fn14 may be an important downstream regulator of HER2/HER3-driven breast cancer cell migration and invasion. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23378579      PMCID: PMC3631278          DOI: 10.1158/1541-7786.MCR-12-0542

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

2.  The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Thomas F Sawyer; Jeffrey A Winkles; Michael E Berens
Journal:  J Biol Chem       Date:  2004-12-16       Impact factor: 5.157

3.  HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1.

Authors:  D G Bosc; B S Goueli; R Janknecht
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

Review 4.  TWEAK and Fn14: new molecular targets for cancer therapy?

Authors:  Jeffrey A Winkles; Nhan L Tran; Michael E Berens
Journal:  Cancer Lett       Date:  2006-04-08       Impact factor: 8.679

5.  Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells.

Authors:  J Yao; S Xiong; K Klos; N Nguyen; R Grijalva; P Li; D Yu
Journal:  Oncogene       Date:  2001-12-06       Impact factor: 9.867

6.  A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia.

Authors:  Manuel Yepes; Sharron A N Brown; Elizabeth G Moore; Elizabeth P Smith; Daniel A Lawrence; Jeffrey A Winkles
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

7.  The EGF/CSF-1 paracrine invasion loop can be triggered by heregulin beta1 and CXCL12.

Authors:  Lorena Hernandez; Tatiana Smirnova; Dmitriy Kedrin; Jeffrey Wyckoff; Liyin Zhu; E Richard Stanley; Dianne Cox; William J Muller; Jeffrey W Pollard; Nico Van Rooijen; Jeffrey E Segall
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 8.  Neuregulins and cancer.

Authors:  Juan Carlos Montero; Ruth Rodríguez-Barrueco; Alberto Ocaña; Elena Díaz-Rodríguez; Azucena Esparís-Ogando; Atanasio Pandiella
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

9.  A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.

Authors:  Si Tuen Lee-Hoeflich; Lisa Crocker; Evelyn Yao; Thinh Pham; Xander Munroe; Klaus P Hoeflich; Mark X Sliwkowski; Howard M Stern
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

10.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Authors:  C Wallasch; F U Weiss; G Niederfellner; B Jallal; W Issing; A Ullrich
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  20 in total

1.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

2.  Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation.

Authors:  Sujatha Gurunathan; Jeffrey A Winkles; Sankar Ghosh; Matthew S Hayden
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

3.  Generation of homologous cell pairs using the oral lymphatic system.

Authors:  Yin-Fei Pu; Lin Wang; Huan-Huan Wu; Huan Bian; Ying-Ying Hong; Yi-Xiang Wang; Chuan-Bin Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.

Authors:  Cynthia Lopez-Haber; Laura Barrio-Real; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Cell Biol       Date:  2016-07-14       Impact factor: 4.272

5.  Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Authors:  Hong Zhou; Walter N Hittelman; Hideo Yagita; Lawrence H Cheung; Stuart S Martin; Jeffrey A Winkles; Michael G Rosenblum
Journal:  Cancer Res       Date:  2013-05-30       Impact factor: 12.701

6.  HER2/HER3 regulates extracellular acidification and cell migration through MTK1 (MEKK4).

Authors:  James J Sollome; Elangovan Thavathiru; Todd D Camenisch; Richard R Vaillancourt
Journal:  Cell Signal       Date:  2013-09-12       Impact factor: 4.315

7.  The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.

Authors:  David S Hersh; Bryan G Harder; Alison Roos; Sen Peng; Jonathan E Heath; Teklu Legesse; Anthony J Kim; Graeme F Woodworth; Nhan L Tran; Jeffrey A Winkles
Journal:  Neuro Oncol       Date:  2018-09-03       Impact factor: 12.300

8.  HER2 mRNA status contributes to the discrepancy between gene amplification and protein overexpression in gastric cancer.

Authors:  Gui-Fen Ma; Yi-Mei Liu; Hong Gao; Qing Miao; Tian-Cheng Luo; Xiao-Qing Zeng; Shi-Yao Chen
Journal:  Dig Dis Sci       Date:  2013-11-02       Impact factor: 3.199

9.  Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.

Authors:  Harshil D Dhruv; Timothy G Whitsett; Nathan M Jameson; Falak Patel; Jeffrey A Winkles; Michael E Berens; Nhan L Tran
Journal:  Carcinogenesis       Date:  2013-08-23       Impact factor: 4.944

10.  Neuregulin1 acts as a suppressor in human lung adenocarcinoma via AKT and ERK1/2 pathway.

Authors:  Youya Wang; Zhifeng Ning; Xuefeng Zhou; Zetian Yang; Hexiao Tang; Ming Xu; Xianguo Wang; Jinping Zhao; Yuting Bai
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.